Unknown

Dataset Information

0

Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of Parkinsonism.

ABSTRACT: Parkinson's disease (PD) is characterized by a progressive degeneration of substantia nigra dopaminergic neurons projecting to the striatum. Restoration of dopamine transmission by L-DOPA relieves symptoms of PD but causes prominent side effects. There is a strong serotonin innervation of the striatum by serotonergic neurons that remains relatively preserved in PD. The study of this innervation has been largely neglected. Here, we demonstrate that chronic L-DOPA administration to 6-OHDA-lesioned rodents increases, via D1 receptors, the levels of the 5-HT1B receptor and its adaptor protein, p11, in dopamine-denervated striatonigral neurons. Using unilaterally 6-OHDA-lesioned p11 WT and KO mice, it was found that administration of a selective 5-HT1B receptor agonist, CP94253, inhibited L-DOPA-induced rotational behavior and abnormal involuntary movements in a p11-dependent manner. These data reveal an L-DOPA-induced negative-feedback mechanism, whereby the serotonin system may influence the symptomatology of Parkinsonism.

SUBMITTER: Zhang X 

PROVIDER: S-EPMC2538893 | biostudies-literature | 2008 Feb

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of Parkinsonism.

Zhang Xiaoqun X   Andren Per E PE   Greengard Paul P   Svenningsson Per P  

Proceedings of the National Academy of Sciences of the United States of America 20080206 6

Parkinson's disease (PD) is characterized by a progressive degeneration of substantia nigra dopaminergic neurons projecting to the striatum. Restoration of dopamine transmission by L-DOPA relieves symptoms of PD but causes prominent side effects. There is a strong serotonin innervation of the striatum by serotonergic neurons that remains relatively preserved in PD. The study of this innervation has been largely neglected. Here, we demonstrate that chronic L-DOPA administration to 6-OHDA-lesioned  ...[more]

Similar Datasets

Unknown p11 modulates L-DOPA therapeutic effects and dyskinesia via distinct cell types in experimental Parkinsonism.
| S-EPMC4747690 | biostudies-other
Unknown Bidirectional regulation of emotional memory by 5-HT1B receptors involves hippocampal p11.
| S-EPMC3781317 | biostudies-literature
Unknown Selective Regulation of 5-HT1B Serotonin Receptor Expression in the Striatum by Dopamine Depletion and Repeated L-DOPA Treatment: Relationship to L-DOPA-Induced Dyskinesias.
| S-EPMC7035192 | biostudies-literature
Unknown The role of GRK6 in animal models of Parkinson's disease and L-DOPA treatment.
| S-EPMC3293148 | biostudies-literature
Unknown The Anti-Parkinsonism Effects of KATP Channel Blockade in the 6-Hydroxydopamine-Induced Animal Model: The Role of Oxidative Stress.
| S-EPMC5535324 | biostudies-other
Unknown Animal Models of Autosomal Recessive Parkinsonism.
| S-EPMC8301401 | biostudies-literature
Unknown Fluoxetine potentiation of methylphenidate-induced gene regulation in striatal output pathways: potential role for 5-HT1B receptor.
| S-EPMC4250300 | biostudies-literature
Unknown Non-dopaminergic Alterations in Depression-Like FSL Rats in Experimental Parkinsonism and L-DOPA Responses.
| S-EPMC7099513 | biostudies-literature
Unknown Cell type-specific plasticity of striatal projection neurons in parkinsonism and L-DOPA-induced dyskinesia.
| S-EPMC4431763 | biostudies-literature
Unknown Inhibition of adenylyl cyclase type 5 prevents L-DOPA-induced dyskinesia in an animal model of Parkinson's disease.
| S-EPMC6608409 | biostudies-literature